

## PRODUCT DATA SHEET

Bioworld Technology CO., Ltd.



### CD30-L (Q103) Peptide

Cat No.: BS2746P

#### Background

The ligand for CD30 is CD30L (CD153). The binding of CD30 to CD30L mediates pleiotropic effects including cell proliferation, activation, differentiation, and apoptotic cell death. CD30 has a critical role in the pathophysiology of Hodgkin's disease and other CD30+ lymphomas. CD30 acts as a costimulatory molecule in thymic negative selection. In addition to its expression on Hodgkin's and Reed-Sternberg cells, CD30 is also found in some non-Hodgkin's lymphomas (including Burkitt's lymphomas), virus-infected T and B cells, and on normal T and B cells after activation. In T cells, CD30 expression is present on a subset of T cells that produce Th2-type cytokines and on CD4+/CD8+ thymocytes that coexpress CD45RO and the IL4 receptor.

#### Swiss-Prot

P32971

#### Applications

Blocking

#### Specificity

This peptide can be used with studies using BS2746 CD30-L (Q103) pAb.

#### Purification & Purity

Synthetic peptide CD30-L (Q103). (Note: the amino acid sequence is proprietary). The purity is > 98%.

#### Product

1 mg/ml in DI water.

#### Storage & Stability

Store at 4 °C short term. Aliquot and store at -20 °C long term. Avoid freeze-thaw cycles.

#### Research Use

For research use only, not for use in diagnostic procedure.